Paratek Pharmaceuticals Inc  

(Public, NASDAQ:PRTK)   Watch this stock  
Find more results for NASDAQ:TSPT
28.87
-0.31 (-1.06%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 28.55 - 29.44
52 week 16.00 - 45.96
Open 29.44
Vol / Avg. 15,478.00/41,602.00
Mkt cap 420.72M
P/E     -
Div/yield 8.01
EPS -10.04
Shares 14.42M
Beta 0.56
Inst. own 81%
May 4, 2015
Q1 2015 Paratek Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Apr 2, 2015
Q4 2014 Paratek Pharmaceuticals Inc Earnings Release
Mar 20, 2015
Paratek Pharmaceuticals Inc at Biocentury Future Leaders in the Biotech Industry
Mar 2, 2015
Paratek Pharmaceuticals Inc at Cowen Health Care Conference
Feb 12, 2015
Paratek Pharmaceuticals Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -103.67% -410.76%
Operating margin 191.04% -179.59%
EBITD margin - -145.65%
Return on average assets -19.15% -32.06%
Return on average equity -33.66% -
Employees 13 -
CDP Score - -

Address

75 Kneeland St Fl 6
BOSTON, MA 02111-1901
United States - Map
+1-617-2750040 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Paratek Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. The Company began a Phase II study of TO-2061, a low dose of ondansetron adjunctive treatment for patients with obsessive compulsive disorder (OCD), who has not adequately responded to first-line therapy. Intermezzo is formulated as a sublingual tablet containing a bicarbonate-carbonate buffer and is absorbed in both women and men. Intermezzo was studied in two Phase III clinical trials involving more than 370 patients. Ambien and its generic equivalents are available in doses of 5 milligram and 10 milligram. Ambien CR and its generic equivalents are available in doses of 6.25 milligram and 12.5 milligram. It has a primary manufacturing and supply agreement with Patheon, Inc. Patheon to manufacture a supply of Intermezzo for use outside the United States.

Officers and directors

Michael F. Bigham CPA Chairman of the Board, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Evan Loh M.D. President, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Douglas W. Pagan Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Kathryn M. Boxmeyer Director
Age: 39
Bio & Compensation  - Reuters
Frederick J. Ruegsegger Independent Director
Age: 58
Bio & Compensation  - Reuters